| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Imbruvica | |
| 3 | Generic | ibrutinib | |
| 4 | Indication | CLL, GvHD, WM | |
| 5 | MOA | BTK inhibitor | |
| 6 | Clinical Trials | ||
| 7 | Phase I/II iMAGINE n=47 pediatric GvHD | ||
| 8 | 60% ORR at week 25 | ||
| 9 | |||
| 10 | |||
| 11 | Phase III "GLOW" ibrutinib+venetoclax vs. chlorambucil+obinutuzumab 1L CLL - NCT03462719 | ||
| 12 | superior PFS, HR=0.216 | ||
| 13 | |||
| 14 | Phase II "CAPTIVATE" ibrutinib+venetoclax - NCT02910583 | ||
| 15 | 1L CLL |